This site is intended for healthcare professionals

Results from phase III DAPA-CKD trial of Farxiga met primary and secondary endpoints to treat chronic kidney disease - AstraZeneca.

Read time: 1 mins
Last updated:29th Jul 2020
Published:29th Jul 2020
Condition: Chronic Kidney Disease/CKD
Type: drug
Register free for full access to